Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Eileen W StalmanLuuk WieskeKoos P J van DamLaura Y KummerZoé L E van KempenJoep KillesteinAdriaan G VolkersSander W TasLaura BoekelGertjan J WolbinkAnneke J Van der KooiJoost RaaphorstMark LöwenbergR Bart TakkenbergGeert R A M D'HaensPhyllis I SpulsMarcel W BekkenkAnnelie H MustersNicoline F PostAngela L BosmaMarc L HilhorstYosta VegtingFrederique J BemelmanAlexandre E VoskuylBo BroensAgner Parra SanchezCécile A C M van ElsJelle De WitAbraham RutgersKarina de LeeuwBarbara HorváthJan J G M VerschuurenAnnabel M RuiterLotte van OuwerkerkDiane van der WoudeC F AllaartY K Onno TengPieter van PaassenMatthias H BuschPapay B P JallahEsther BrussePieter A van DoornAdája Elisabeth BaarsDirk Jan HijnenCorine R G SchreursW Ludo Van der PolH Stephan GoedeeMaurice SteenhuisSofie KeijzerJim B D KeijserArend BoogaardOlvi CristianawatiAnja Ten BrinkeNiels J M VerstegenKoos A H ZwindermanTheo RispensS Marieke van HamTaco W KuijpersFilip Eftimovnull nullPublished in: Annals of the rheumatic diseases (2022)
The cumulative incidence of reported SARS-CoV-2 omicron breakthrough infections was high, but similar between patients with IMID on immunosuppressants and controls, and disease severity was mostly mild. Additional vaccinations and prior SARS-CoV-2 infections may reduce the incidence of breakthrough infections.